PURPOSE: Mammalian target of rapamycin (mTOR) plays a central role in cell proliferation and is regarded as a promising target in cancer therapy, including for ovarian cancer. This study aimed to examine the role of mTOR as a therapeutic target in clear cell carcinoma of the ovary, which is regarded as an aggressive, chemoresistant histologic subtype. EXPERIMENTAL DESIGN: Using tissue microarrays of 98 primary ovarian cancers (52 clear cell carcinomas and 46 serous adenocarcinomas), the expression of phospho-mTOR was assessed by immunohistochemistry. Then, the growth-inhibitory effect of mTOR inhibition by RAD001 (everolimus) was examined using two pairs of cisplatin-sensitive parental (RMG1 and KOC7C) and cisplatin-resistant human clear cell carcinoma cell lines (RMG1-CR and KOC7C-CR) both in vitro and in vivo. RESULTS: Immunohistochemical analysis showed that mTOR was more frequently activated in clear cell carcinomas than in serous adenocarcinomas (86.6% versus 50%). Treatment with RAD001 markedly inhibited the growth of both RMG1 and KOC7C cells both in vitro and in vivo. Increased expression of phospho-mTOR was observed in cisplatin-resistant RMG1-CR and KOC7C-CR cells, compared with the respective parental cells. This increased expression of phospho-mTOR in cisplatin-resistant cells was associated with increased activation of AKT. RMG1-CR and KOC7C-CR cells showed greater sensitivity to RAD001 than did parental RMG1 and KOC7C cells, respectively, in vitro and in vivo. CONCLUSION: mTOR is frequently activated in clear cell carcinoma and can be a promising therapeutic target in the management of clear cell carcinoma. Moreover, mTOR inhibition by RAD001 may be efficacious as a second-line treatment of recurrent disease in patients previously treated with cisplatin.
PURPOSE:Mammalian target of rapamycin (mTOR) plays a central role in cell proliferation and is regarded as a promising target in cancer therapy, including for ovarian cancer. This study aimed to examine the role of mTOR as a therapeutic target in clear cell carcinoma of the ovary, which is regarded as an aggressive, chemoresistant histologic subtype. EXPERIMENTAL DESIGN: Using tissue microarrays of 98 primary ovarian cancers (52 clear cell carcinomas and 46 serous adenocarcinomas), the expression of phospho-mTOR was assessed by immunohistochemistry. Then, the growth-inhibitory effect of mTOR inhibition by RAD001 (everolimus) was examined using two pairs of cisplatin-sensitive parental (RMG1 and KOC7C) and cisplatin-resistant humanclear cell carcinoma cell lines (RMG1-CR and KOC7C-CR) both in vitro and in vivo. RESULTS: Immunohistochemical analysis showed that mTOR was more frequently activated in clear cell carcinomas than in serous adenocarcinomas (86.6% versus 50%). Treatment with RAD001 markedly inhibited the growth of both RMG1 and KOC7C cells both in vitro and in vivo. Increased expression of phospho-mTOR was observed in cisplatin-resistant RMG1-CR and KOC7C-CR cells, compared with the respective parental cells. This increased expression of phospho-mTOR in cisplatin-resistant cells was associated with increased activation of AKT. RMG1-CR and KOC7C-CR cells showed greater sensitivity to RAD001 than did parental RMG1 and KOC7C cells, respectively, in vitro and in vivo. CONCLUSION:mTOR is frequently activated in clear cell carcinoma and can be a promising therapeutic target in the management of clear cell carcinoma. Moreover, mTOR inhibition by RAD001 may be efficacious as a second-line treatment of recurrent disease in patients previously treated with cisplatin.
Authors: Iwan Beuvink; Anne Boulay; Stefano Fumagalli; Frederic Zilbermann; Stephan Ruetz; Terence O'Reilly; Francois Natt; Jonathan Hall; Heidi A Lane; George Thomas Journal: Cell Date: 2005-03-25 Impact factor: 41.582
Authors: K Ueki; R Yamamoto-Honda; Y Kaburagi; T Yamauchi; K Tobe; B M Burgering; P J Coffer; I Komuro; Y Akanuma; Y Yazaki; T Kadowaki Journal: J Biol Chem Date: 1998-02-27 Impact factor: 5.157
Authors: Shi-Yong Sun; Laura M Rosenberg; Xuerong Wang; Zhongmei Zhou; Ping Yue; Haian Fu; Fadlo R Khuri Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701
Authors: B C Behrens; T C Hamilton; H Masuda; K R Grotzinger; J Whang-Peng; K G Louie; T Knutsen; W M McKoy; R C Young; R F Ozols Journal: Cancer Res Date: 1987-01-15 Impact factor: 12.701
Authors: Deborah A Altomare; Hui Qin Wang; Kristine L Skele; Assunta De Rienzo; Andres J Klein-Szanto; Andrew K Godwin; Joseph R Testa Journal: Oncogene Date: 2004-07-29 Impact factor: 9.867
Authors: Pradip K Majumder; Phillip G Febbo; Rachel Bikoff; Raanan Berger; Qi Xue; Louis M McMahon; Judith Manola; James Brugarolas; Timothy J McDonnell; Todd R Golub; Massimo Loda; Heidi A Lane; William R Sellers Journal: Nat Med Date: 2004-05-23 Impact factor: 53.440
Authors: Molly K Altman; Ali A Alshamrani; Wei Jia; Ha T Nguyen; Jada M Fambrough; Sterling K Tran; Mihir B Patel; Pooya Hoseinzadeh; Aaron M Beedle; Mandi M Murph Journal: Cancer Lett Date: 2015-08-28 Impact factor: 8.679
Authors: Kian Behbakht; Michael W Sill; Kathleen M Darcy; Stephen C Rubin; Robert S Mannel; Steven Waggoner; Russell J Schilder; Kathy Q Cai; Andrew K Godwin; R Katherine Alpaugh Journal: Gynecol Oncol Date: 2011-07-12 Impact factor: 5.482
Authors: Ankur K Nagaraja; Chad J Creighton; Zhifeng Yu; Huifeng Zhu; Preethi H Gunaratne; Jeffrey G Reid; Emuejevoke Olokpa; Hiroaki Itamochi; Naoto T Ueno; Shannon M Hawkins; Matthew L Anderson; Martin M Matzuk Journal: Mol Endocrinol Date: 2010-01-15